$
MFST
Medifirst Solutions Applauds the Passage of the Farm Bill at the American Pain Association Symposium in Philadelphia
GlobeNewswire•December 17, 2018
Freehold, NJ, Dec. 17, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- MEDIFIRST SOLUTIONS, INC. ( MFST ) (the “Company” or “Medifirst”): Speaking at the American Pain Association (APA) symposium held on December 12th at the PCOM Medical School in Philadelphia, Bruce J. Schoengood, President of Medifirst Solutions, applauded the passage of the Farm Bill by the Senate. Stated Schoengood, “We believe that this historical legislation will make it easier for CBD manufacturing and distribution companies like Medifirst to enter the market and provide access to Hemp and CBD products for people in need and will open the door for further research and insurance coverage for CBD.”
This symposium was part of the APA National Medical School Educational Tour Initiative, started to educate, advocate and fight the deadly opioid epidemic that has been responsible for killing thousands and putting innocent youths and children at serious risk. Topics discussed included the challenges and strategies for stemming the Opioid Epidemic and exploring the role of CBD products in pain management.
Speaking at the Symposium, Dr. Sanjay Gupta, President of the American Pain Association said, “There is still lot of stigma and poor education among physicians and the public about CBD products and its full potential is not being realized. I believe the research has clearly shown the benefits of Cannabis products in various medical conditions including pain management. Many doctors and patients, I believe, incorrectly still feel that CBD is more harmful than opioids. It is my position that there is no reason to categorize CBD as a scheduled drug as it has no addiction potential.” The American Pain Association is currently initiating several studies on CBD in conjunction with various prestigious Medical school faculties across North America. Continued Dr. Gupta, “Many patients can’t afford CBD and as a result, they choose harmful opioids just because they are paid by their insurance plans. That is why I am in discussions with insurance companies to address these most important issues and concerns. If Insurance companies are willing to pay for harmful opioids, they should consider paying for harmless yet effective alternatives like CBD. The passage of the Farm Bill is a significant step in helping patients and in curbing the opioid epidemic.”
Richard J. Hollawell, a trial attorney in Philadelphia, presented at the conference. He believes that although most medical professionals are doing a great job, some may be potentially harming patients by over prescribing harmful opioids. Stated Hollawell, “I believe these practices are not being monitored effectively by the DEA and Medical Licensing Boards. There are practitioners whose patients have died from opioids, but they continue to practice without any enforcement action. Often, the families of these patients are filled with guilt and shame in dealing with addiction. They feel that it was their loved one’s fault and therefore many do not pursue legal action. I believe there are unethical practices within the medical community that must be stopped as they are hurting the reputation of many good doctors, healthcare professionals and pharmaceutical companies.”
The next symposium of the American Pain Association (APA) National Medical School Tour will be held on December 18th at Rutgers RWJ Medical School. Doctors and healthcare professionals and interested people are welcome to attend on Tuesday, December 18, 2018, 5-8pm at RWJ University Hospital, New Brunswick, NJ. Please note that Dr. Sanjay Gupta of the APA is not related to Dr. Gupta of CNN.
About The Time Machine Laser
Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for “The Time Machine” Series Laser, received clearance from the U.S. Food and Drug Administration (“FDA”) to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions. The hand-held laser device, with pin-point accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. Visit www.medifirstsolutions.com for more information. Follow on Twitter @Medi_First and for Facebook visit Medifirst Solutions.
Forward-Looking Statements:
The statements in this press release that relate to the company’s expectations about the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control. Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission. Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.
Contact: Investor Relations
Phone: (732) 786-8044
Email: admin@medifirstsolutions.com
Website: www.medifirstsolutions.com
GlobeNewswire•December 17, 2018
Freehold, NJ, Dec. 17, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- MEDIFIRST SOLUTIONS, INC. ( MFST ) (the “Company” or “Medifirst”): Speaking at the American Pain Association (APA) symposium held on December 12th at the PCOM Medical School in Philadelphia, Bruce J. Schoengood, President of Medifirst Solutions, applauded the passage of the Farm Bill by the Senate. Stated Schoengood, “We believe that this historical legislation will make it easier for CBD manufacturing and distribution companies like Medifirst to enter the market and provide access to Hemp and CBD products for people in need and will open the door for further research and insurance coverage for CBD.”
This symposium was part of the APA National Medical School Educational Tour Initiative, started to educate, advocate and fight the deadly opioid epidemic that has been responsible for killing thousands and putting innocent youths and children at serious risk. Topics discussed included the challenges and strategies for stemming the Opioid Epidemic and exploring the role of CBD products in pain management.
Speaking at the Symposium, Dr. Sanjay Gupta, President of the American Pain Association said, “There is still lot of stigma and poor education among physicians and the public about CBD products and its full potential is not being realized. I believe the research has clearly shown the benefits of Cannabis products in various medical conditions including pain management. Many doctors and patients, I believe, incorrectly still feel that CBD is more harmful than opioids. It is my position that there is no reason to categorize CBD as a scheduled drug as it has no addiction potential.” The American Pain Association is currently initiating several studies on CBD in conjunction with various prestigious Medical school faculties across North America. Continued Dr. Gupta, “Many patients can’t afford CBD and as a result, they choose harmful opioids just because they are paid by their insurance plans. That is why I am in discussions with insurance companies to address these most important issues and concerns. If Insurance companies are willing to pay for harmful opioids, they should consider paying for harmless yet effective alternatives like CBD. The passage of the Farm Bill is a significant step in helping patients and in curbing the opioid epidemic.”
Richard J. Hollawell, a trial attorney in Philadelphia, presented at the conference. He believes that although most medical professionals are doing a great job, some may be potentially harming patients by over prescribing harmful opioids. Stated Hollawell, “I believe these practices are not being monitored effectively by the DEA and Medical Licensing Boards. There are practitioners whose patients have died from opioids, but they continue to practice without any enforcement action. Often, the families of these patients are filled with guilt and shame in dealing with addiction. They feel that it was their loved one’s fault and therefore many do not pursue legal action. I believe there are unethical practices within the medical community that must be stopped as they are hurting the reputation of many good doctors, healthcare professionals and pharmaceutical companies.”
The next symposium of the American Pain Association (APA) National Medical School Tour will be held on December 18th at Rutgers RWJ Medical School. Doctors and healthcare professionals and interested people are welcome to attend on Tuesday, December 18, 2018, 5-8pm at RWJ University Hospital, New Brunswick, NJ. Please note that Dr. Sanjay Gupta of the APA is not related to Dr. Gupta of CNN.
About The Time Machine Laser
Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for “The Time Machine” Series Laser, received clearance from the U.S. Food and Drug Administration (“FDA”) to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions. The hand-held laser device, with pin-point accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. Visit www.medifirstsolutions.com for more information. Follow on Twitter @Medi_First and for Facebook visit Medifirst Solutions.
Forward-Looking Statements:
The statements in this press release that relate to the company’s expectations about the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control. Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission. Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.
Contact: Investor Relations
Phone: (732) 786-8044
Email: admin@medifirstsolutions.com
Website: www.medifirstsolutions.com
What I post is my opinion. Do your own DD. Make your own investment decision. Links, images, & retweets are not endorsements.
1️⃣I do not provide personal investment advice and I am not a qualified licensed investment advisor. I am an amateur investor.
2️⃣All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies.
3️⃣I will not and cannot be held liable for any actions you take as a result of anything you read here.
4️⃣Conduct your own due diligence, or consult a licensed financial advisor or broker before making any and all investment decisions. Any investments, trades, speculations, or decisions made on the basis of any information found on this site, expressed or implied herein, are committed at your own risk, financial or otherwise.
4️⃣Not Financial Advice. What I post is my opinion.
Also Paid for Advertising/IR/PR on Emerging Companies
Full Disclaimer: https://corporateads.com/disclaimer/
1️⃣I do not provide personal investment advice and I am not a qualified licensed investment advisor. I am an amateur investor.
2️⃣All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies.
3️⃣I will not and cannot be held liable for any actions you take as a result of anything you read here.
4️⃣Conduct your own due diligence, or consult a licensed financial advisor or broker before making any and all investment decisions. Any investments, trades, speculations, or decisions made on the basis of any information found on this site, expressed or implied herein, are committed at your own risk, financial or otherwise.
4️⃣Not Financial Advice. What I post is my opinion.
Also Paid for Advertising/IR/PR on Emerging Companies
Full Disclaimer: https://corporateads.com/disclaimer/
